Metabolic Disorders Therapeutics-Asia Pacific Market Status and Trend Report 2013-2023
SKU ID :MI-11647228 | Published Date: 17-Jan-2018 | No. of pages: 153Description
TOC
Table of Contents
Chapter 1 Overview of Metabolic Disorders Therapeutics
1.1 Definition of Metabolic Disorders Therapeutics in This Report
1.2 Commercial Types of Metabolic Disorders Therapeutics
1.2.1 Metachromatic Leukodystrophy
1.2.2 Globoid Leukodystrophy
1.2.3 Hepatic Encephalopathy
1.2.4 Others
1.3 Downstream Application of Metabolic Disorders Therapeutics
1.3.1 Diabetes
1.3.2 Obesity
1.3.3 Hypercholesterolemia
1.3.4 Lysosomal storage diseases
1.4 Development History of Metabolic Disorders Therapeutics
1.5 Market Status and Trend of Metabolic Disorders Therapeutics 2013-2023
1.5.1 Asia Pacific Metabolic Disorders Therapeutics Market Status and Trend 2013-2023
1.5.2 Regional Metabolic Disorders Therapeutics Market Status and Trend 2013-2023
Chapter 2 Asia Pacific Market Status and Forecast by Regions
2.1 Market Status of Metabolic Disorders Therapeutics in Asia Pacific 2013-2017
2.2 Consumption Market of Metabolic Disorders Therapeutics in Asia Pacific by Regions
2.2.1 Consumption Volume of Metabolic Disorders Therapeutics in Asia Pacific by Regions
2.2.2 Revenue of Metabolic Disorders Therapeutics in Asia Pacific by Regions
2.3 Market Analysis of Metabolic Disorders Therapeutics in Asia Pacific by Regions
2.3.1 Market Analysis of Metabolic Disorders Therapeutics in China 2013-2017
2.3.2 Market Analysis of Metabolic Disorders Therapeutics in Japan 2013-2017
2.3.3 Market Analysis of Metabolic Disorders Therapeutics in Korea 2013-2017
2.3.4 Market Analysis of Metabolic Disorders Therapeutics in India 2013-2017
2.3.5 Market Analysis of Metabolic Disorders Therapeutics in Southeast Asia 2013-2017
2.3.6 Market Analysis of Metabolic Disorders Therapeutics in Australia 2013-2017
2.4 Market Development Forecast of Metabolic Disorders Therapeutics in Asia Pacific 2018-2023
2.4.1 Market Development Forecast of Metabolic Disorders Therapeutics in Asia Pacific 2018-2023
2.4.2 Market Development Forecast of Metabolic Disorders Therapeutics by Regions 2018-2023
Chapter 3 Asia Pacific Market Status and Forecast by Types
3.1 Whole Asia Pacific Market Status by Types
3.1.1 Consumption Volume of Metabolic Disorders Therapeutics in Asia Pacific by Types
3.1.2 Revenue of Metabolic Disorders Therapeutics in Asia Pacific by Types
3.2 Asia Pacific Market Status by Types in Major Countries
3.2.1 Market Status by Types in China
3.2.2 Market Status by Types in Japan
3.2.3 Market Status by Types in Korea
3.2.4 Market Status by Types in India
3.2.5 Market Status by Types in Southeast Asia
3.2.6 Market Status by Types in Australia
3.3 Market Forecast of Metabolic Disorders Therapeutics in Asia Pacific by Types
Chapter 4 Asia Pacific Market Status and Forecast by Downstream Industry
4.1 Demand Volume of Metabolic Disorders Therapeutics in Asia Pacific by Downstream Industry
4.2 Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in Major Countries
4.2.1 Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in China
4.2.2 Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in Japan
4.2.3 Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in Korea
4.2.4 Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in India
4.2.5 Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in Southeast Asia
4.2.6 Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in Australia
4.3 Market Forecast of Metabolic Disorders Therapeutics in Asia Pacific by Downstream Industry
Chapter 5 Market Driving Factor Analysis of Metabolic Disorders Therapeutics
5.1 Asia Pacific Economy Situation and Trend Overview
5.2 Metabolic Disorders Therapeutics Downstream Industry Situation and Trend Overview
Chapter 6 Metabolic Disorders Therapeutics Market Competition Status by Major Players in Asia Pacific
6.1 Sales Volume of Metabolic Disorders Therapeutics in Asia Pacific by Major Players
6.2 Revenue of Metabolic Disorders Therapeutics in Asia Pacific by Major Players
6.3 Basic Information of Metabolic Disorders Therapeutics by Major Players
6.3.1 Headquarters Location and Established Time of Metabolic Disorders Therapeutics Major Players
6.3.2 Employees and Revenue Level of Metabolic Disorders Therapeutics Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
Chapter 7 Metabolic Disorders Therapeutics Major Manufacturers Introduction and Market Data
7.1 Novo Nordisk
7.1.1 Company profile
7.1.2 Representative Metabolic Disorders Therapeutics Product
7.1.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Novo Nordisk
7.2 Sanofi
7.2.1 Company profile
7.2.2 Representative Metabolic Disorders Therapeutics Product
7.2.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Sanofi
7.3 Merck
7.3.1 Company profile
7.3.2 Representative Metabolic Disorders Therapeutics Product
7.3.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Merck
7.4 AstraZeneca
7.4.1 Company profile
7.4.2 Representative Metabolic Disorders Therapeutics Product
7.4.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of AstraZeneca
7.5 Eli Lily
7.5.1 Company profile
7.5.2 Representative Metabolic Disorders Therapeutics Product
7.5.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Eli Lily
7.6 AbbVie
7.6.1 Company profile
7.6.2 Representative Metabolic Disorders Therapeutics Product
7.6.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of AbbVie
7.7 Actelion Pharmaceuticals
7.7.1 Company profile
7.7.2 Representative Metabolic Disorders Therapeutics Product
7.7.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Actelion Pharmaceuticals
7.8 Adocia
7.8.1 Company profile
7.8.2 Representative Metabolic Disorders Therapeutics Product
7.8.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Adocia
7.9 Aegerion Pharmaceuticals
7.9.1 Company profile
7.9.2 Representative Metabolic Disorders Therapeutics Product
7.9.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Aegerion Pharmaceuticals
7.10 Akros Pharma
7.10.1 Company profile
7.10.2 Representative Metabolic Disorders Therapeutics Product
7.10.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Akros Pharma
7.11 Alnylam Pharmaceuticals
7.11.1 Company profile
7.11.2 Representative Metabolic Disorders Therapeutics Product
7.11.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Alnylam Pharmaceuticals
7.12 Amarin
7.12.1 Company profile
7.12.2 Representative Metabolic Disorders Therapeutics Product
7.12.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Amarin
7.13 Amicus Therapeutics
7.13.1 Company profile
7.13.2 Representative Metabolic Disorders Therapeutics Product
7.13.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Amicus Therapeutics
7.14 Biopharma
7.14.1 Company profile
7.14.2 Representative Metabolic Disorders Therapeutics Product
7.14.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Biopharma
7.15 Arena Pharmaceuticals
7.15.1 Company profile
7.15.2 Representative Metabolic Disorders Therapeutics Product
7.15.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Arena Pharmaceuticals
7.16 Astellas Pharma
7.17 Bionaturis
7.18 Diasome Pharmaceuticals
7.19 Lexicon Pharmaceuticals
7.20 Ligand Pharmaceuticals
Chapter 8 Upstream and Downstream Market Analysis of Metabolic Disorders Therapeutics
8.1 Industry Chain of Metabolic Disorders Therapeutics
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
Chapter 9 Cost and Gross Margin Analysis of Metabolic Disorders Therapeutics
9.1 Cost Structure Analysis of Metabolic Disorders Therapeutics
9.2 Raw Materials Cost Analysis of Metabolic Disorders Therapeutics
9.3 Labor Cost Analysis of Metabolic Disorders Therapeutics
9.4 Manufacturing Expenses Analysis of Metabolic Disorders Therapeutics
Chapter 10 Marketing Status Analysis of Metabolic Disorders Therapeutics
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
Chapter 11 Report Conclusion
Chapter 12 Research Methodology and Reference
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
Tables & Figures
List of Tables
Table Advantage and Disadvantage of Metachromatic Leukodystrophy
Table Advantage and Disadvantage of Globoid Leukodystrophy
Table Advantage and Disadvantage of Hepatic Encephalopathy
Table Advantage and Disadvantage of Others
Table Consumption Volume of Metabolic Disorders Therapeutics in Asia Pacific by Regions 2013-2017
Table Revenue of Metabolic Disorders Therapeutics in Asia Pacific by Regions 2013-2017
Table Consumption Volume of Metabolic Disorders Therapeutics in Asia Pacific by Regions 2018-2023
Table Revenue of Metabolic Disorders Therapeutics in Asia Pacific by Regions 2018-2023
Table Consumption Volume of Metabolic Disorders Therapeutics in Asia Pacific by Types 2013-2017
Table Revenue of Metabolic Disorders Therapeutics in Asia Pacific by Types 2013-2017
Table Consumption Volume of Metabolic Disorders Therapeutics by Types in China 2013-2017
Table Consumption Volume of Metabolic Disorders Therapeutics by Types in Japan 2013-2017
Table Consumption Volume of Metabolic Disorders Therapeutics by Types in Korea 2013-2017
Table Consumption Volume of Metabolic Disorders Therapeutics by Types in India 2013-2017
Table Consumption Volume of Metabolic Disorders Therapeutics by Types in Southeast Asia 2013-2017
Table Consumption Volume of Metabolic Disorders Therapeutics by Types in Australia 2013-2017
Table Consumption Volume Forecast of Metabolic Disorders Therapeutics in Asia Pacific by Types 2018-2023
Table Revenue Forecast of Metabolic Disorders Therapeutics in Asia Pacific by Types 2018-2023
Table Demand Volume of Metabolic Disorders Therapeutics in Asia Pacific by Downstream Industry 2013-2017
Table Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in China 2013-2017
Table Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in Japan 2013-2017
Table Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in Korea 2013-2017
Table Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in India 2013-2017
Table Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in Southeast Asia 2013-2017
Table Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in Australia 2013-2017
Table Demand Volume Forecast of Metabolic Disorders Therapeutics in Asia Pacific by Downstream Industry 2018-2023
Table Sales Volume of Metabolic Disorders Therapeutics in Asia Pacific by Major Players 2013-2017
Table Revenue of Metabolic Disorders Therapeutics in Asia Pacific by Major Players 2013-2017
Table Headquarters Location and Established Time of Metabolic Disorders Therapeutics Major Players
Table Employees and Revenue Level of Metabolic Disorders Therapeutics Major Players
Table Representative Metabolic Disorders Therapeutics Product One of Novo Nordisk
Table Representative Metabolic Disorders Therapeutics Product Two of Novo Nordisk
Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Novo Nordisk 2013-2017
Table Representative Metabolic Disorders Therapeutics Product One of Sanofi
Table Representative Metabolic Disorders Therapeutics Product Two of Sanofi
Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Sanofi 2013-2017
Table Representative Metabolic Disorders Therapeutics Product One of Merck
Table Representative Metabolic Disorders Therapeutics Product Two of Merck
Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Merck 2013-2017
Table Representative Metabolic Disorders Therapeutics Product One of AstraZeneca
Table Representative Metabolic Disorders Therapeutics Product Two of AstraZeneca
Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of AstraZeneca 2013-2017
Table Representative Metabolic Disorders Therapeutics Product One of Eli Lily
Table Representative Metabolic Disorders Therapeutics Product Two of Eli Lily
Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Eli Lily 2013-2017
Table Representative Metabolic Disorders Therapeutics Product One of AbbVie
Table Representative Metabolic Disorders Therapeutics Product Two of AbbVie
Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of AbbVie 2013-2017
Table Representative Metabolic Disorders Therapeutics Product One of Actelion Pharmaceuticals
Table Representative Metabolic Disorders Therapeutics Product Two of Actelion Pharmaceuticals
Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Actelion Pharmaceuticals 2013-2017
Table Representative Metabolic Disorders Therapeutics Product One of Adocia
Table Representative Metabolic Disorders Therapeutics Product Two of Adocia
Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Adocia 2013-2017
Table Representative Metabolic Disorders Therapeutics Product One of Aegerion Pharmaceuticals
Table Representative Metabolic Disorders Therapeutics Product Two of Aegerion Pharmaceuticals
Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Aegerion Pharmaceuticals 2013-2017
Table Representative Metabolic Disorders Therapeutics Product One of Akros Pharma
Table Representative Metabolic Disorders Therapeutics Product Two of Akros Pharma
Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Akros Pharma 2013-2017
Table Representative Metabolic Disorders Therapeutics Product One of Alnylam Pharmaceuticals
Table Representative Metabolic Disorders Therapeutics Product Two of Alnylam Pharmaceuticals
Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Alnylam Pharmaceuticals 2013-2017
Table Representative Metabolic Disorders Therapeutics Product One of Amarin
Table Representative Metabolic Disorders Therapeutics Product Two of Amarin
Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Amarin 2013-2017
Table Representative Metabolic Disorders Therapeutics Product One of Amicus Therapeutics
Table Representative Metabolic Disorders Therapeutics Product Two of Amicus Therapeutics
Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Amicus Therapeutics 2013-2017
Table Representative Metabolic Disorders Therapeutics Product One of Biopharma
Table Representative Metabolic Disorders Therapeutics Product Two of Biopharma
Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Biopharma 2013-2017
Table Representative Metabolic Disorders Therapeutics Product One of Arena Pharmaceuticals
Table Representative Metabolic Disorders Therapeutics Product Two of Arena Pharmaceuticals
Table Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Arena Pharmaceuticals 2013-2017
Companies
- PRICE
-
$3480$5980Buy Now